Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…